Russian Direct Investment Fund, Hetero Labs agree to produce Sputnik V COVID Vaccine In India

Share on:

Russia’s sovereign wealth fund and Indian pharmaceutical company Hetero, according to a statement on Sputnik V’s Twitter account on Friday agreed to produce over 100 million doses of the Sputnik V vaccine against Covid-19 in India. Hetero and the Russian Direct Investment Fund (RDIF), which have been backing and marketing the vaccine globally, plan to start production of the vaccine in India at the beginning of 2021, the statement said. Apart from India, Sputnik v will also be produced in Brazil, China, and South Korea, the RDIF said.

According to RDIF head, Kirill Dmitriyev was also quoted in Friday’s statement saying that Sputnik V should become an integral part of the national vaccine portfolio of every country willing to protect its population from the coronavirus.

“While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients”, said Hetero Director B. Murali Krishna. Indian drugmaker, Dr. Reddy’s Laboratories Ltd, currently conducting the final phase trials of the vaccine in India, said it expected late-stage trial results to be finalized as early as March 2021.

Earlier this week, on Tuesday, the RDIF and the Gamaleya National Center said that interim results from clinical trials of the vaccine appeared to show a 95% rate of efficacy by day 42, similar to other international vaccine trial results, many of which showed an efficacy rate of 90% and higher. It also announced that the vaccine would be priced at $10 per dose in international markets, less than many other registered Covid-19 vaccines.

Leave a Reply

Your email address will not be published.